Advertisement

Nutraceuticals in Acute and Prophylactic Treatment of Migraine

  • Oved DanielEmail author
  • Alexander Mauskop
Headache (JR Couch, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Headache

Opinion statement

People who suffer from headaches often prefer nutraceutical treatment over traditional pharmacological approaches, due to fear of possible side effects, drug dependence, or addiction. Since treatment with nutraceuticals does not require a doctor’s prescription, many patients rely on their own judgment as to when and which one to take, often without consultation or guidance from their physician. Some physicians could provide information about potential efficacy and side effects of various products, but many are not familiar with the nutraceuticals. Widespread skepticism persists among doctors about the effectiveness of these treatments. This is largely due to the lack of rigorous clinical studies. However, even when incontrovertible scientific evidence exists, many physicians remain distrustful of the evidence. The following review summarizes randomized controlled trials of some of the most commonly used non-pharmacological treatments, including magnesium, coenzyme Q10, riboflavin (vitamin B2), petasites, and feverfew (Table 1).

Keywords

Nutraceuticals Headache Migraine Vitamins Minerals Herbal preparation 

Notes

Compliance with Ethical Standards

Conflict of Interest

Oved Daniel and Alexander Mauskop declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia. 2010;30:065–1072.CrossRefGoogle Scholar
  2. 2.
    Steiner TJ, Birbeck GL, Jensen RH, Katsarava Z, Stovner LJ, Martelletti P. Headache disorders are third cause of disability worldwide. J Headache Pain. 2015;16(1):1–3.CrossRefGoogle Scholar
  3. 3.
    Diener HC, Solbach K, Holle D, Gaul C. Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options. Clin Med. 2015;15(4):344–50.Google Scholar
  4. 4.
    Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population Burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71(8):559–66.CrossRefPubMedGoogle Scholar
  5. 5.
    GöKSEL BK. The use of complementary and alternative medicine in patients with migraine. Arch Neuropsychiatr. 2013;50 Suppl 1:S41–6.CrossRefGoogle Scholar
  6. 6.•
    Tepper SJ. Nutraceutical and other modalities for the treatment of headache. CONTINUUM: Lifelong Learn Neurol. 2015;21(4, Headache):1018–31. A very comprehensive review on complementary treatment modalities for migraine (not only nutraceuticals).Google Scholar
  7. 7.
    Sun‐Edelstein C, Mauskop A. Alternative headache treatments: nutraceuticals, behavioral and physical treatments. Headache: J Head Face Pain. 2011;51(3):469–83.CrossRefGoogle Scholar
  8. 8.
    Mauskop A. Nonmedication, alternative, and complementary treatments for migraine. CONTINUUM: Lifelong Learn Neurol. 2012;18(4, Headache):796–806.Google Scholar
  9. 9.
    Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH, et al. Magnesium in the prophylaxis of migraine—a double-blind, placebo-controlled study. Cephalalgia. 1996;16(6):436–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996;16(4):257–63.CrossRefPubMedGoogle Scholar
  11. 11.
    Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia. 2002;22(5):345–53.CrossRefPubMedGoogle Scholar
  12. 12.
    Hershey AD, Powers SW, Vockell AB, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache. 2007;47:73–80.CrossRefPubMedGoogle Scholar
  13. 13.
    Schoenen J, Jacquy J, Lanaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. Neurology. 1998;50:466–70.CrossRefPubMedGoogle Scholar
  14. 14.
    Pothmann R, Danesch U. Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache. 2005;45:196–203.CrossRefPubMedGoogle Scholar
  15. 15.
    Grossmann M, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther. 2000;38(9):430–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Lipton RB, Gobel H, Einhaupl KM, Wilks K, Mauskop A. Petsites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology. 2004;63:2240–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke‐von Zepelin HH. Efficacy and safety of 6.25 mg tid feverfew CO2‐extract (MIG‐99) in migraine prevention—a randomized, double‐blind, multicentre, Placebo‐controlled study. Cephalalgia. 2005;25(11):1031–41.CrossRefPubMedGoogle Scholar
  18. 18.
    Pfaffenrath V, Diener HC, Fisher M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis— a double-blind, multicentre, randomized placebo-controlled dose–response study. Cephalalgia. 2002;22:523–5322.CrossRefPubMedGoogle Scholar
  19. 19.
    Lea R, Colson N, Quinlan S, Macmillan J, Griffiths L. The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability. Pharmacogenet Genomics. 2009;19(6):422–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Schimatschek HF, Rempis R. Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. Magnes Res: Off Organ Int Soc Dev Res Magnes. 2001;14(4):283–90.Google Scholar
  21. 21.
    Ramadan NM, Halvorson H, Vande-Linde A, et al. Low brain magnesium in migraine. Headache. 1989;29:590–3.CrossRefPubMedGoogle Scholar
  22. 22.
    Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulfate relieves acute migraine in patients with low serum ionized magnesium levels. Clin Sci. 1995;89:633–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Gallai V, Sarchielli P, Morucci P, Abbritti G. Red blood cell magnesium levels in migraine patients. Cephalalgia. 1993;13(2):94–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Gallai V, Sarchielli P, Morucci P, Abbritti G. Magnesium content of mononuclear blood cells in migraine patients. Headache: J Head Face Pain. 1994;34(3):160–5.CrossRefGoogle Scholar
  25. 25.
    Trauninger A, Pfund Z, Koszegi T, Czopf J. Oral magnesium load test in patients with migraine. Headache. 2002;42:114–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Storer RJ, Goadsby PJ. N-Methyl-D-Aspartate receptor channel complex blockers including memantine and magnesium inhibit nociceptive traffic in the trigeminocervical complex of the rat. Cephalalgia. 2009;29:135.CrossRefGoogle Scholar
  27. 27.••
    Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1346–53. An extensive analysis of published studies from June 1999 to May 2009 that provides evidenced based recommendations for the preventive treatment of migraines.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Choi H, Parmar N. The use of intravenous magnesium sulphate for acute migraine: meta-analysis of randomized controlled trials. Eur J Emerg Med. 2014;21(1):2–9.PubMedGoogle Scholar
  29. 29.
    Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Schechter AL, et al. Open label trial of Coenzyme Q10 as a migraine preventive. Cephalalgia. 2002;22:137–41.CrossRefPubMedGoogle Scholar
  30. 30.
    Sandor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64(4):713–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Di Lorenzo C, Pierelli F, Coppola G, Grieco GS, Rengo C, Ciccolella, et al. Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology. 2009;72(18):1588–94.CrossRefPubMedGoogle Scholar
  32. 32.
    Pringsheim T, Davenport W, Mackie G, Worthington I, Aubé M, Christie, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39(2 Suppl 2):S1–59.PubMedGoogle Scholar
  33. 33.
    Heptinstall S, Williamson L, White A, Mitchell JRA. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet. 1985;325(8437):1071–4.CrossRefGoogle Scholar
  34. 34.
    Heptinstall S, Goenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behaviour via neutralisation of suphydryl groups. J Pharm Pharmacol. 1987;39:459–65.CrossRefPubMedGoogle Scholar
  35. 35.
    Pugh WH, Sambo K. Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol. 1988;40:743–5.CrossRefPubMedGoogle Scholar
  36. 36.
    Makheja AM, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins Leukot Med. 1982;8:653–60.PubMedGoogle Scholar
  37. 37.
    Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J. 1985;291:569–73.CrossRefGoogle Scholar
  38. 38.
    Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988;2:189–92.CrossRefPubMedGoogle Scholar
  39. 39.
    Kuritzky A, Elhacham Y, Yerushalmi Z, Hering R. Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. Neurology. 1994;44 Suppl 2:293.Google Scholar
  40. 40.
    De Weerdt CJ, Bootsma HPR, Hendriks H. Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine. 1996;3(3):225–30.CrossRefPubMedGoogle Scholar
  41. 41.
    Palevitch D, Earon G, Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a placebo-controlled doulbe-blind study. Phytother Res. 1997;11:508–11.CrossRefGoogle Scholar
  42. 42.
    Vogler BK, Pittler BK, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia. 1998;18:704–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Draves AH, Walker SE. Parthenolide content of Canadian commercial feverfew preparations: label claims are misleading in most cases. CPJ, Can Pharm J. 2003;136(10):23–30.Google Scholar
  44. 44.
    Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata. Clin Pharmacokinet. 2011;50(6):349–69.CrossRefPubMedGoogle Scholar
  45. 45.
    Lampl C, Haider B, Schweiger C. Long-term efficacy of Boswellia serrata in four patients with chronic cluster headache. Cephalalgia. 2012;32(9):719–22.CrossRefPubMedGoogle Scholar
  46. 46.
    Plaza HRC. Late-Breaking Abstracts. 2014.Google Scholar
  47. 47.
    Bekkelund SI, Alstadhaug KB. Migraine prophylactic drugs-something new under the sun. Expert Opin Investig Drugs. 2011;20(9):1201–10.CrossRefPubMedGoogle Scholar
  48. 48.
    Peres M, Goncalves A. Double-blind, placebo controlled, randomized clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. Neurology. 2013;80(Meeting Abstracts 1):S40–005.Google Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Headache & Facial Pain Clinic, Laniado Medical CenterNetanyaISRAEL
  2. 2.Clinical NeurologySUNY Downstate Medical CenterBrooklynUSA
  3. 3.New York Headache CenterNew YorkUSA

Personalised recommendations